# contextual query Anti-inflammatory TAMs

Query: The following is a list of genes enriched in tumour microenvironment cells from a (human) patient with glioblastoma  annotated as Myeloid.  What might this list say about the state, properties and interactions of this cell type?  Do not limit your answers to the cancer literature,  include normal cell-cell interactions, development and cross-cutting metabolic states.  Gene list: ['SAT1', 'TBXAS1', 'MERTK', 'CD163', 'MS4A6A', 'MSR1', 'MS4A7', 'SLCO2B1', 'FMN1', 'ARHGAP15']

The genes you provided—**SAT1, TBXAS1, MERTK, CD163, MS4A6A, MSR1, MS4A7, SLCO2B1, FMN1, ARHGAP15**—are characteristic of myeloid populations, including macrophages and monocyte-derived cells, particularly within the context of the glioblastoma (GBM) tumor microenvironment. Analysis of these genes provides key insights into the **state, properties, and interactions** of these cells, both in tumors and in normal biology.

### Immunological State and Functional Properties

- **Immunosuppressive Phenotype**  
  - **CD163** and **MSR1 (CD204)** are well-established markers of anti-inflammatory (alternatively activated, M2-like) macrophages. These cells are known to suppress immune responses, facilitate tissue remodeling, and promote tumor progression through secretion of anti-inflammatory cytokines and clearance of cellular debris[1].
  - **MERTK** is a receptor tyrosine kinase involved in the clearance of apoptotic cells (efferocytosis) and the maintenance of tissue homeostasis. Its expression in tumor-associated myeloid cells contributes to immune suppression by dampening proinflammatory responses and promoting tolerance within the TME[1].
  - **MS4A6A** and **MS4A7** are part of the membrane-spanning 4A gene family, often co-expressed in monocytes and macrophages. Their exact function remains unclear, but they are increasingly recognized as markers of mature, immunomodulatory myeloid cells, particularly in disease contexts including cancer and chronic inflammation.
  - **SLCO2B1** encodes an organic anion transporter that regulates prostaglandin and eicosanoid metabolism, suggesting adaptation to the inflammatory and hypoxic TME, where lipid mediators play a regulatory role in immune suppression[4].
  - **TBXAS1** encodes thromboxane synthase, which is involved in arachidonic acid metabolism and the generation of thromboxane A2, a molecule with roles in platelet aggregation, vascular tone, and potentially immunosuppressive signaling.

- **Metabolic Adaptation and Stress Response**  
  - **SAT1** (spermidine/spermine N1-acetyltransferase 1) regulates polyamine catabolism. Polyamines are essential for cellular proliferation and differentiation, and their catabolism is involved in the response to oxidative stress—a common feature of the TME. Upregulated SAT1 indicates an adaptation to metabolic stress, likely supporting cell survival and function under hypoxia and nutrient limitation[4].
  - **FMN1** (formin 1) and **ARHGAP15** (Rho GTPase activating protein 15) are regulators of actin cytoskeleton dynamics, which are crucial for cell migration, phagocytosis, and the establishment of cell-cell contacts—key for immune surveillance, antigen presentation, and tissue remodeling.

### Developmental and Homeostatic Context

- In *normal physiology*, **CD163**, **MSR1**, and **MERTK** are crucial for the transition of monocytes to tissue macrophages with reparative, homeostatic, and anti-inflammatory roles. These genes are highly expressed in tissue macrophages of the brain (microglia) and other organs, where they enable the resolution of inflammation and maintenance of tissue integrity.
- **MS4A6A/MS4A7** and metabolic genes like **SAT1** reflect differentiation toward a mature, resident macrophage phenotype adapted for tissue-specific functions beyond immune defense, such as synaptic pruning in the CNS and wound healing.

### Cell-Cell and Tumor-Host Interactions

- In glioblastoma, these myeloid cells interact with tumor cells and other stroma through:
  - **Clearance of dead/dying cells** (via MERTK, MSR1), providing trophic support and preventing secondary necrosis that could alert the immune system.
  - **Immunosuppression** (CD163, anti-inflammatory cytokines), which protects the tumor from cytotoxic T cell attack and supports tumor immune evasion[1][3].
  - **Angiogenesis and tissue remodeling** (TBXAS1, MS4A7), supporting tumor growth and invasion through paracrine effects on endothelial and stromal cells[3].

### Cross-Cutting Metabolic States

- Tumor-associated myeloid cells adapt to the metabolic constraints of the TME, showing:
  - **Enhanced polyamine turnover** (SAT1), likely supporting both rapid cell turnover and protection from oxidative damage[4].
  - **Altered lipid and prostaglandin metabolism** (SLCO2B1, TBXAS1), which can modulate both local inflammation and vascular responses.
  - **Cytoskeletal plasticity** (FMN1, ARHGAP15), enhancing mobility and phagocytic capacity required for dynamic tissue environments.

### Summary Table

| Gene         | Key Function                          | Implication in TME                          |
|--------------|---------------------------------------|---------------------------------------------|
| SAT1         | Polyamine catabolism                  | Metabolic adaptation, oxidative stress      |
| TBXAS1       | Thromboxane, eicosanoid synthesis     | Vascular, immune modulation                 |
| MERTK        | Efferocytosis, tolerance              | Immune suppression, debris clearance        |
| CD163        | Scavenger receptor, anti-inflammation | M2-like, immunosuppressive macrophages      |
| MS4A6A/MS4A7 | Myeloid cell surface markers          | Mature, regulatory macrophages/monocytes    |
| MSR1         | Scavenger receptor                    | Anti-inflammatory, homeostatic functions    |
| SLCO2B1      | Eicosanoid, prostaglandin transport   | Lipid mediator signaling, metabolic stress  |
| FMN1         | Cytoskeletal remodeling               | Migration, phagocytosis, cell interaction   |
| ARHGAP15     | Rho GTPase regulation                 | Motility, cytoskeletal dynamics             |

These signatures reveal a population of **differentiated, immunosuppressive, metabolically adaptive myeloid cells** within the glioblastoma TME, supporting tumor progression by modulating the immune environment, facilitating cell debris clearance, and adapting to metabolic and environmental stress[1][3][4]. These properties echo their roles in normal development and tissue maintenance but are co-opted in the tumor context to favor tumor survival and growth.



## References

- [1] IMMU-25. ANALYSIS OF IMMUNOSUPPRESSIVE MYELOID CELLS IN THE GLIOBLASTOMA TUMOR MICROENVIRONMENT REVEALS THERAPEUTICALLY TARGETABLE IMMUNOMODULATORY SIGNALS ACROSS POPULATIONS https://academic.oup.com/neuro-oncology/article/25/Supplement_5/v147/7406141 2023-11-01 None
- [2] OS07.1.A INTEGRATIVE SINGLE NUCLEI, SPATIAL, AND FUNCTIONAL GENOMIC ANALYSES REVEAL DNA-PK DRIVES GLIOBLASTOMA RADIORESISTANCE THROUGH TUMOR CELLS AND THE MYELOID MICROENVIRONMENT https://academic.oup.com/neuro-oncology/article/26/Supplement_5/v22/7825124 2024-10-01 None
- [3] Insights into the glioblastoma tumor microenvironment: current and emerging therapeutic approaches https://www.frontiersin.org/articles/10.3389/fphar.2024.1355242/full 2024-03-08 None
- [4] Metabolic adaptation of myeloid cells in the glioblastoma microenvironment https://www.frontiersin.org/articles/10.3389/fimmu.2024.1431112/full 2024-12-23 None
- [5] TMIC-20. UNLOCKING THE POTENTIAL OF HYPOXIA REDUCTION IN RESHAPING THE GLIOBLASTOMA TUMOR MICROENVIRONMENT FOR ENHANCED THERAPEUTIC SYNERGY https://academic.oup.com/neuro-oncology/article/26/Supplement_8/viii301/7890215 2024-11-01 None